Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD274
  • Antineoplastic Agents
  • Urinary Bladder Neoplasms
  • Urothelium

abstract

  • Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, many of whom were heavily pretreated.

publication date

  • September 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5569690

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.67.9761

PubMed ID

  • 27269937

Additional Document Info

start page

  • 3119

end page

  • 25

volume

  • 34

number

  • 26